151 / 1084
USA – CALGB 80803
Key results
Treatment course by induction therapy
Induction
mFOLFOX
(n=129)
PET responder
73/129 (57%)
PET non-responder
39/129 (30%)
Induction
carboplatin/paclitaxel
(n=128)
PET responder
64/128 (50%)
PET non-responder
49/128 (38%)
35
© Universitätsmedizin Leipzig: University Cancer Center Leipzig (UCCL), Prof. Dr. F. Lordick
Goodman KA, et al. J Clin Oncol 2017; 35 (suppl 4): abstr 1
*Evaluable patients
Concurrent mFOLFOX
64/73* (86%)
Surgery
n=58
Concurrent
carboplatin/paclitaxel
37/39* (95%)
Surgery
n=27
Concurrent
carboplatin/paclitaxel
56/64* (86%)
Surgery
n=49
Concurrent mFOLFOX
41/49* (84%)
Surgery
n=32